Arthritogenic alphaviruses comprise a group of enveloped RNA viruses that are transmitted to humans by mosquitoes and cause debilitating acute and chronic musculoskeletal disease 1 . The host factors required for alphavirus entry remain poorly characterized 2 . Here we use a genome-wide CRISPR-Cas9-based screen to identify the cell adhesion molecule Mxra8 as an entry mediator for multiple emerging arthritogenic alphaviruses, including chikungunya, Ross
vaccine strain 12 that has acquired heparan sulfate binding activity 13 , we evaluated Mxra8 with other CHIKV strains. Infection of CHIKV-AF15561-the parental Asian strain of CHIKV-181/25, which binds poorly to heparan sulfate 14 -and CHIKV-37997, a West African genotype strain, was abolished in ΔMxra8 3T3 cells, reduced in ΔMxra8 MEF cells ( Fig. 1a ) and restored in trans-complemented ΔMxra8 3T3 cells (Fig. 1b, c) . However, the dependence on Mxra8 was less with CHIKV-LR 2006, a strain of the East/Central/South African genotype ( Fig. 1a, d ). To confirm that CHIKV required Mxra8 independently of heparan sulfate binding, we expressed murine Mxra8 in parental or glycosaminoglycan-deficient Chinese hamster ovary cells 15 (Extended Data Fig. 3a ). Expression of Mxra8 enhanced infectivity of CHIKV regardless of whether Chinese hamster ovary cells expressed heparan sulfate or other glycosaminoglycans (Extended Data Fig. 3b, c) .
We tested the requirement of Mxra8 for infection by other alphaviruses. Whereas Mayaro, Ross River, O'nyong nyong and Barmah Forest arthritogenic alphaviruses showed reduced infection in ΔMxra8 3T3 cells, Semliki Forest and Getah viruses had partial phenotypes, and other related alphaviruses (Sindbis, Bebaru, Una and Middleburg viruses) showed little dependence on Mxra8 ( Fig. 1e and Extended Data Fig. 4 ). Minimal differences in infection were observed between control and ΔMxra8 3T3 cells with chimaeric Sindbis viruses expressing the structural genes of the Eastern or Western equine encephalitis alphaviruses, or a Venezuelan equine encephalitis virus that expressed GFP (Fig. 1e ). No effect of Mxra8 was seen on infection of unrelated positive-or negative-sense RNA viruses ( Fig. 1f ). We next assessed whether any of the four isoforms of the human MXRA8 orthologue (Extended Data Fig. 1b ) served a similar function. As HeLa cells did not express MXRA8 (Extended Data Fig. 5 ), we used these cells for ectopic expression (Extended Data Fig. 6a ). MXRA8-1, MXRA8-2 and MXRA8-4-but not MXRA8-3-were detected on the cell surface, and MXRA8-1 and MXRA8-2 enhanced CHIKV infectivity (Fig. 1g) . Similarly, expression of MXRA8-2 in A549 or 293T cells resulted in greater CHIKV infection (Extended Data Fig. 6b, c) . Consistent with this observation, expression of different sgRNAs targeting all isoforms of MXRA8 in MRC-5 human lung fibroblasts, HFF-1 foreskin fibroblasts, RPE retinal pigment epithelial cells and Hs 633T fibrosarcoma cells resulted in less CHIKV infection than in control gene-edited cells ( Fig. 1h and Extended Data Fig. 7a, b) .
To determine whether Mxra8 is required for replication, we transfected CHIKV genomic RNA into control and ΔMxra8 MEF cells in the presence of NH 4 Cl to inhibit virus maturation and further rounds of infection. As no difference in CHIKV gene expression was detected ( Fig. 2a ), Mxra8 does not appear to affect translation or replication. We demonstrated an Mxra8-dependence of the structural proteins using pseudotyped viruses. Whereas infection of CHIKV pseudotyped virions that encapsidated a murine leukaemia virus GFP-reporter RNA Letter reSeArCH was reduced in ΔMxra8 compared to control MEF cells, infection of Eastern or Western equine encephalitis virus pseudotyped virions was not ( Fig. 2b ). Consistent with a role for Mxra8 in the entry pathway, at 4 °C CHIKV-AF15561 showed reduced binding to ΔMxra8 compared to control MEF cells, and increased binding to cells overexpressing Mxra8 (Fig. 2c, d) . When virus internalization assays were performed at 37 °C, less CHIKV RNA was measured within ΔMxra8 MEF cells, and more CHIKV RNA was detected in cells overexpressing Mxra8 (Fig. 2c) .
To corroborate an effect of Mxra8 on binding and entry, we generated Fc fusion proteins with the extracellular domains of mouse Mxra8 (Mxra8-Fc) or human MXRA8-2 (MXRA8-2-Fc), along with a control osteoprotegerin protein (OPG-Fc) (Extended Data Fig. 8a ). Pre-incubation with Mxra8-Fc or MXRA8-2-Fc, but not the control OPG-Fc, reduced CHIKV-181/25 infection in 3T3 ( Fig. 2e ) and MRC-5 ( Fig. 2f ) cells. We tested a panel of hamster mAbs against mouse Mxra8 (Extended Data Fig. 8b ) for their capacity to inhibit CHIKV infection. Seven mAbs bound to mouse Mxra8-Fc, with four also recognizing human MXRA8-2-Fc (Extended Data Fig. 8c ). Pre-treatment of 3T3 cells with anti-Mxra8 mAbs reduced CHIKV infection (Fig. 2g ). Three of the mAbs that bound human MXRA8-2-Fc also reduced infection in MRC-5 cells (Extended Data Fig. 8d ). To establish the importance of the Mxra8 ectodomain, we engineered forms with glycophosphatidylinositol anchors (Mxra8-GPI) or lacking a cytoplasmic domain (Mxra8-ΔC-tail) for trans-complementation (Extended Data Fig. 9 ). Notably, Mxra8-GPI and Mxra8-ΔC-tail restored CHIKV infection ( Fig. 2h ). Interaction with the Mxra8 ectodomain may facilitate viral glycoprotein conformational changes that are required for internalization or fusion 16 or potentiate interactions with other host factors that bridge membrane penetration and entry 17 . Finally, heterologous expression of human MXRA8-2 in ΔMxra8 mouse cells also restored CHIKV infection ( Fig. 2h ).
To determine whether Mxra8 directly binds to CHIKV, we captured virions or virus-like particles 18 with a human anti-CHIKV mAb 19 , and added Mxra8-Fc or MXRA8-2-Fc in an enzyme-linked immunosorbent assay. Both Mxra8-Fc and MXRA8-2-Fc, but not OPG-Fc, bound to CHIKV virions and virus-like particles ( Fig. 3a, b ). By comparison, Mxra8-Fc and MXRA8-2-Fc did not bind efficiently to Eastern equine encephalitis virus particles derived from a chimaera with Sindbis virus (Fig. 3c ). In a complementary assay, we assessed binding of Mxra8-Fc protein to cell-surface-displayed alphavirus proteins on infected cells 19, 20 Fig. 10a, b ). We also analysed binding of Mxra8 to CHIKV virus-like particles by surface plasmon resonance, and found a slow association rate, a long half-life and an affinity of about 200 nM ( Fig. 3d ).
. Mxra8-Fc bound cells infected with CHIKV, O'nyong nyong virus, Mayaro virus and Ross River virus, but not cells infected with Sindbis virus or Venezuelan equine encephalitis virus (Extended Data
We evaluated whether human anti-CHIKV mAbs that bound epitopes within the E2 protein 19 altered Mxra8-Fc binding to CHIKV. Several mAbs recognizing epitopes in the A domain (2H1, 8G18, 3E23 and 1O6) and mAbs recognizing shared epitopes in the A and B domains (1H12 and 4J14) inhibited binding, whereas other mAbs that localize to distinct sites had less effect ( Fig. 3e ). We then tested Table 3 ). Data are from two experiments. ****P < 0.0001.
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the binding of Mxra8-Fc to an alanine scanning mutagenesis library of E2 A and B domains in the context of display on the surface of 293T cells 19, 20 . Residues W64, D71, T116 and I121 in the A domain, and I190, Y199 and I217 in the B domain, of E2 emerged as essential for optimal Mxra8-Fc binding ( Fig. 3f and Supplementary Table 3 ) and overlap the binding sites of the blocking mAbs that we tested 19 .
Mapping of these residues onto the p62 (E2 precursor)-E1 heterodimer or the trimer of heterodimers (Extended Data Fig. 10c, d ) on the virion surface 21 revealed a solvent-accessible epitope across the top of the A and B domains, which is a proposed site of alphavirus receptor engagement 22, 23 .
To begin to assess the physiological importance of MXRA8 interaction with CHIKV, we tested surface expression of MXRA8 on primary human keratinocytes, dermal fibroblasts, synovial fibroblasts, osteoblasts, chondrocytes and skeletal muscle cells ( Fig. 4a ), all of which are targets of infection by alphaviruses 24 . Pretreatment with anti-MXRA8 blocking mAbs inhibited infection of CHIKV-AF15561 in all cells but keratinocytes, which lack MXRA8 expression ( Fig. 4a, b ). We next evaluated whether co-injection of Mxra8-Fc with CHIKV-AF15561 would diminish infection in C57BL/6 mice. The addition of Mxra8-Fc diminished CHIKV infection in the ipsilateral ankle and muscle ( Fig. 4c ) and reduced foot swelling ( Fig. 4d ) compared to a control mAb. Treatment with Mxra8-Fc also inhibited O'nyong nyong virus infection in the ipsilateral ankle of mice ( Fig. 4e ). We next administered Mxra8-Fc via an intraperitoneal route, and 6 h later we inoculated CHIKV in the footpad. Mxra8-Fc treatment reduced foot swelling and viral burden in the ipsilateral ankle ( Fig. 4f, g) , although the phenotype was less pronounced than *P < 0.05; **P < 0.01; ***, P < 0.001; ****P < 0.0001.
in co-injection experiments. To extend these findings, we transferred hamster anti-Mxra8 blocking or control mAbs to mice via an intraperitoneal route 12 h before CHIKV inoculation. Reduced CHIKV titres were observed in the ipsilateral ankle and calf muscle, and contralateral ankle at 12 and 72 h after infection in anti-Mxra8 compared to control mAb-treated mice (Fig. 4h ). Treatment with anti-Mxra8 mAbs also reduced foot swelling ( Fig. 4i ). In post-exposure therapeutic experiments, we observed reduced CHIKV infection in the contralateral ankle and muscle when anti-Mxra8 mAbs were administered at 8 or 24 h after virus inoculation ( Fig. 4j and Extended Data Fig. 8e ). These in vivo experiments establish a function for Mxra8 in the pathogenesis of infection of arthritogenic alphaviruses.
Our studies establish that mouse Mxra8 contributes to CHIKV entry and is required for infection and disease. Human MXRA8 also bound CHIKV and supported infection, and MXRA8 expression in primary human cells overlapped with the tropism of CHIKV in vivo. Infection of several arthritogenic alphaviruses-including CHIKV, O'nyong nyong virus, Mayaro virus and Ross River virus-was reduced in ΔMxra8 cells, which suggests that Mxra8 may serve as a shared receptor. Our data contrast with those relating to natural resistance-associated macrophage protein (NRAMP2), which is an entry receptor for Sindbis virus but not for CHIKV or Ross River virus 25 . Nonetheless, residual CHIKV infection in the absence of Mxra8 in cells and in mice, and the absence of an apparent mosquito orthologue, suggests that additional unidentified host factors contribute to cell binding and entry.
Our mutagenesis mapping studies suggest that amino acids in the E2 A and B domains contribute to the interaction of CHIKV with Mxra8. Higher-resolution structural experiments are needed to define the complete footprint of binding between Mxra8 and CHIKV E2 protein. Such studies could facilitate the development of small molecules or biological agents that disrupt Mxra8 interaction with E2 protein, which could form the basis of therapeutic strategies for the amelioration of diseases caused by multiple emerging alphaviruses.
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MEthodS Cells and viruses. Vero, NIH-3T3, MEF, HEK 293T, A549, HeLa (ATCC #CCL-2), MRC-5 (provided by D. Wang, Washington University), HFF-1 (ATCC #SCRC-1041), Hs 633T (Sigma-Aldrich #89050201), Huh7, RPE (provided by M. Mahjoub, Washington University), JEG3 (provided by I. Mysorekar, Washington University), U2OS (provided by S. Cherry, University of Pennsylvania), HT1080 (provided by J. Cooper, Washington University), Raji and K562 cells all were cultured at 37 °C in Dulbecco's Modified Eagle medium supplemented with 10% fetal bovine serum (FBS), 10 mM HEPES, 1 mM sodium pyruvate, 1× non-essential amino acids, and 100 U/ml of penicillin-streptomycin. HTR8/SV.neo cells (provided by I. Mysorekar, Washington University) were cultured in RPMI 1640 supplemented with 5% FBS and 1% penicillin and streptomycin. Jurkat cells were cultured at 37 °C in RPMI 1640 supplemented with 10% FBS and 10 mM HEPES. hCMEC/ D3 cells (provided by R. Klein, Washington University) were cultured in EBM-2 medium (Lonza, 00190860) supplemented with 5% FBS, 5 μg/ml ascorbic acid, 10 mM HEPES, 1% lipid concentrate (Gibco, 11905-031) in plates pre-coated with collagen. All cell lines were tested and found to be free of mycoplasma contamination using a commercial kit. Cell lines were not authenticated.
Primary human keratinocytes (#102-05n), synovial fibroblasts (#408-05a), osteoblasts (#406-05f), chondrocytes (#402-05f) and skeletal muscle cells (#S150-05f) were purchased from Cell Applications. Primary human dermal fibroblasts (#CC-2509) were obtained from Lonza. Cells were thawed and cultured in specified medium according to the instructions of the manufacturers, and used within one week.
The . Replicationcompetent SINV chimaeric viruses were constructed by replacing the SINV TR339 structural protein genes with EEEV FL93-939 or WEEV Fleming structural protein genes under control of the SINV subgenomic promoter in the TR339 cDNA clone 27 . All viruses were propagated in Vero cells and titrated by standard plaque or focus-forming assays 28 . Pooled sgRNA screen and data analysis. A GeCKOv2 CRISPR knockout pooled library encompassing 130,209 different sgRNAs against 20,611 mouse genes 29 was made available by F. Zhang (Addgene #1000000053), and amplified in Endura cells (Lucigen # 60242) as previously described 29, 30 . The sgRNA library was divided in half (A + B), packaged into lentiviruses and used for independent screening. The sgRNA plasmid library was packaged in 293FT cells after co-transfection with psPAX2 (Addgene #12260) and pMD2.G (Addgene #12259) at a ratio of 2:2:1 using FugeneHD (Promega). Approximately 48 h after transfection, supernatants were collected, clarified by centrifugation (3,500 r.p.m. ×20 min) and aliquotted for storage at −80 °C.
For the CRISPR screen, a clonal 3T3-Cas9 cell line was generated by transduction with a packaged lentivirus (lentiCas9-Blast, Addgene #52962), blasticidin selection and limiting dilution. 3T3-Cas9 cells were expanded and transduced with CRISPR sgRNA lentivirus library at a multiplicity of infection (MOI) of 0.3 by spinoculation (1,000g) at 32 °C for 30 min in 12-well plates. After selection with puromycin for 7 days, ~1 × 10 8 cells were inoculated with CHIKV-181/25-mKate2 (MOI of 1) and then incubated for 24 h to allow nearly all cells to become infected. Cells were sorted for an absence of mKate2 expression using a Sony Biotechnology Synergy SY3200 Cell sorter (Siteman Flow Cytometry Core, Washington University). To enrich for the cell population that was resistant to CHIKV infection and increase the signal-to-noise ratio, the mKate2-negative cells were expanded in culture. Given the rapid replication rate and cytopathic effect of CHIKV, two humanized neutralizing mAbs 5 , CHK-152 and CHK-166 (2 μg/ml of each), were added to block infection by any residual virus. The expanded cells were re-infected with CHIKV-181/25-mKate2 in the absence of mAbs, sorted for mKate2 negative cells and the procedure was repeated for one additional round.
Genomic DNA was extracted from the uninfected cells (5 × 10 7 ) or the mKate2-negative sorted cells (1 × 10 7 ), and sgRNA sequences were amplified 31 and subjected to next generation sequencing using an Illumina HiSeq 2500 platform (Genome Technology Access Center, Washington University). The sgRNA sequences against specific genes were determined after removal of the tag sequences using the FASTX-Toolkit (http://hannonlab.cshl.edu/fastx_toolkit/) and cutadapt 1.8.1. sgRNA sequences were analysed using a published computational tool (MAGeCK) 6 (see Supplementary Tables 1, 2) . Gene validation. Mxra8 was validated by using three independent sgRNAs as follows: Mxra8 sgRNA1, 5′-CTTGTGGATATGTATTCGGC-3′; Mxra8 sgRNA2, 5′-TGTGCGCCTCGAGGTTACAG-3′; Mxra8 sgRNA3, 5′-GCTGCATG ATCGCCAGCGCG-3′. The sgRNAs were cloned into the plasmid lentiCRISPR v.2 (Addgene #52961) and packaged with a lentivirus express system. 3T3 or MEF cells were transduced with lentiviruses expressing individual sgRNA and selected with puromycin for seven days before infection with different viruses. For some validation experiments, clonal cells edited by sgRNA1 were isolated by limiting dilution. To validate the human orthologue MXRA8, two different sgRNAs targeting all four isoforms were used: MXRA8 sgRNA1, 5′-GGCGCGGATGCCTTTGAGCG-3′; MXRA8 sgRNA2, 5′-GTCCGCCTGGAGGTCACCGA-3′. The sgRNAs were cloned similarly as above, and the gene-edited bulk cells were used for validation studies.
For flow cytometric analyses, gene-edited 3T3 cells were inoculated with different viruses as follows: CHIKV-181/25 (MOI of 3, 9. Validation also was performed by an infectious virus yield assay. Gene-edited 3T3 cells were plated 12 h before infection. Cells were inoculated with CHIKV-181/25, CHIKV AF15561, CHIKV-LR 2006 at an MOI of 0.01 or other alphaviruses (BEBV, MOI 0.001; BFV, GETV, UNAV, MIDV, and SFV, all at MOI of 0.01) for 1 h, then washed once and maintained in reduced 2% FBS culture medium. Supernatants were collected at specific times after infection for titration on Vero cells by focus-forming assay (CHIKV) or standard plaque assay (all other viruses). Genomic RNA transfection and analysis. To assess for effects of Mxra8 on CHIKV replication, we transfected capped viral genomic RNA into MEF cells. Capped genomic RNA was generated using an mMESSAGE mMACHINE SP6 Transcription Kit according to the manufacturer's instructions (Thermo Fisher #AM1340) from the NotI-linearized CHIKV-181/25 cDNA clone. One microgram of purified RNA was transfected into control or ΔMxra8 cells using the Neon transfection system according to the manufacturer's instructions (Thermo Fisher Scientific). Cells were then incubated in 15 mM NH 4 Cl to prevent subsequent rounds of infection. At specified times, cells were collected with trypsin and processed for E2 expression levels by flow cytometry. Pseudotyped virus experiments. MLV-GFP pseudoviruses were made as described 33, 34 except plasmids encoding structural proteins of CHIKV (strain 37997), VEEV (strain TrD) and EEEV (strain FL91-4697) were used. Pseudovirus entry in 3T3 cells expressing or lacking Mxra8 was assessed 36 h later by measuring GFP expression by flow cytometry. Plasmid construction. The C-terminal Flag-tagged mouse Mxra8 corresponding to the transcript (NM_024263) was synthesized (Integrated DNA Technologies) and cloned into the lentivirus vector pCSII-EF1-IRES-Venus with restriction sties NotI/BamHI. The Mxra8 sgRNA target sequences were mutated (cttgtggatatgtattcggcg to ctGgtCgaCatgtaCAGCgcg) to avoid re-cutting by Cas9 protein for the trans-complementation. Based on this plasmid, a truncation lacking the cytoplasmic domain was constructed by PCR-mediated mutagenesis, the ΔC-tail (378-442). To express the GPI-anchored Mxra8, the N-terminal 336 amino acids missing the transmembrane and cytoplasmic domains were fused with PLAP (ctggcgccccccgccggcaccaccgacgccgcgcacccggggcggtccgtggtccccgcgttgcttcctctgctggccgggaccctgctgctgctggagacggccactgctccc) or the rodent herpesvirus Peru (RHVP) open reading frame R1 gene (tacccatacgatgttccagattacgctacgtcctcaccatccattggcggcccaaacatgactttactattggccatgatcatgtttgcgttaaagatagggtcg, HA tag Letter reSeArCH is underlined) GPI anchor sequences. To assess the function of different human MXRA8 isoforms, the cDNA of isoform 2 (NM_032348.3) containing C-terminal Myc and Flag tags was purchased from OriGene (Cat. No. RC200955), and cloned into the lentivirus vector pCSII-EF1-IRES-Venus. Isoform 1 (NM_001282585.1), isoform 3 (NM_001282584.1) and isoform 4 (NM_001282583.1) were created by either mutagenesis of isoform 2 or gene synthesis (Integrated DNA Technologies), and cloned into the lentivirus vector pCSII-EF1-IRES-Venus containing C terminus Myc and Flag tags. Trans-complementation and ectopic expression experiments. The plasmids constructed above were packaged using the lentivirus expression system. Cells transduced with these lentiviruses were sorted for Venus-positive cells by flow cytometry. 3T3 cells were inoculated with CHIKV-181/25 (MOI 3) for 9. . Cells were seeded at 5 × 10 6 cells per ml one day before transfection. Two hundred micrograms of plasmid was diluted in Opti-MEM (Thermo Fisher) and complexed with HYPE-5 transfection reagent before addition to cells. Transfected cells were supplemented daily with Expi293 medium and 2% (w/v) Hyclone Cell Boost. Four days after transfection, supernatant was collected, centrifuged at 3,000g for 15 min, and purified by protein A sepharose 4B (Thermo Fisher) chromatography. After elution and buffer neutralization, the purified protein was dialysed into 20 mM HEPES, 150 mM NaCl (pH 7.5), filtered through a 0.20-μm filter, and stored at −80 °C. Mxra8 that was cleaved from the IgG backbone was generated by inserting an HRV cleavage sequence (LEVLFQGP) into Mxra8-Fc downstream of the Mxra8 coding sequence and before the mouse IgG sequence. Mxra8-HRV-Fc was expressed in Expi293 cells as described above. After purification, Mxra8-HRV-Fc was cleaved using HRV 3C protease (Thermo Fisher) at a 1:10 ratio overnight at 4 °C. Cleaved Fc fragments were depleted using protein A sepharose chromatography, and the purity of Mxra8 was confirmed using SDS-PAGE analysis. Expression of CHIKV virus-like particles. The CHIKV virus-like particles plasmid (strain 37997) was provided by G. Nabel (via the Vaccine Research Center, NIH) and expressed in Expi293 cells as previously described 18 . The supernatant was collected four days after transfection, 0.2-μm filtered and stored at 4 °C. ELISA-based Mxra8-Fc binding assays. Anti-CHIKV human mAb 4N12 19 or anti-EEEV human mAb 53 (J.E.C., unpublished data) were immobilized (50 μl, 2 μg/ml) onto Maxisorp ELISA plates (Thermo Fisher) overnight in sodium bicarbonate buffer, pH 9.3. Plates were washed four times with PBS and blocked with PBS supplemented with 4% BSA for 1 h at room temperature. CHIKV-181/25 or SINV-EEEV was diluted to 1.5 × 10 7 FFU per ml in PBS and 50 μl per well was added for 1 h at room temperature. Mxra8-Fc and respective positive (CHK-11 5 and EEEV-10 (A.S.K. and M.S.D., unpublished results) and negative OPC-Fc (D.H.F., unpublished results) controls were diluted in PBS supplemented with 2% BSA and incubated for 1 h at room temperature. After serial washes with PBS, plates were incubated with horseradish peroxide conjugated goat anti-mouse IgG (H + L) (1:2000 dilution, Jackson ImmunoResearch) for 1 h at room temperature. After washing with PBS, plates were developed with 3,3′-5,5′ tetramethylbenzidine substrate (Dako) and 2N H 2 SO 4 . Absorbance was read at 450 nm with a TriStar Microplate Reader (Berthold). The mAb competition binding assay was performed by incubating 10 μg/ml of indicated anti-CHIKV human mAbs 19 for 30 min before the addition of mMxra8-Fc, as described above; the anti-CHIKV human mAbs were mapped previously to different epitopes by alanine scanning mutagenesis and evaluated for neutralizing activity 19 . Humanized anti-WNV mAb E16 32 was included as a negative control in competition binding assays. Surface plasmon resonance based Mxra8 binding assay. Surface plasmon resonance binding experiments were performed on a Biacore T200 system (GE Healthcare) to measure the kinetics and affinity of Mxra8 binding to CHIKV viruslike particles. Experiments were performed at 30 μl/min and 25 °C using 0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% v/v surfactant P20 as running buffer. CHK-265 mAb 5 was immobilized onto a CM5 sensor chip (GE Healthcare) using standard amine coupling chemistry, and CHIKV virus-like particles were captured. Recombinant Mxra8 was injected over a range of concentrations (1 μM to 20 nM) for 5 min followed by a 10 min dissociation period. As a negative control, murine norovirus was captured with mAb A6.2, as previously described 35 . Realtime data were analysed using BIAevaluation 3.1 (GE Healthcare). Kinetic profiles and steady-state equilibrium concentration curves were fitted using a global 1:1 binding algorithm with drifting baseline. Cell-based Mxra8-Fc binding assay. 3T3 cells were inoculated with different viruses at the following MOI: CHIKV-181/25 (MOI of 3, 9.5 h), ONNV (MOI of 5, 12 h), MAYV (MOI of 3, 24 h), RRV (MOI of 3, 32 h), SINV (MOI of 10, 9 h) and VEEV (MOI of 3, 6.5 h). Cells were detached using TrypLE (Thermo Fisher #12605010), washed twice with cold HBSS supplemented with 15 mM HEPES and 2% FBS. Cells were incubated with 1 μg/ml of Mxra8-Fc, OPG-Fc or viral E2-specific antibodies at 4 °C for 25 min. After washing, cells were stained with goat anti-mouse IgG (H + L) conjugated with Alexa Fluor 647 for 25 min at 4 °C. After washing twice, cells were fixed with 2% PFA for 10 min at room temperature. After two additional washes, cells were subjected to flow cytometry analysis. Virus binding and internalization assays. The assays were conducted in suspension. MEF cells were collected using TrypLE and washed twice with ice-cold medium supplemented with 2% FBS. CHIKV-AF15561 virions were purified through a 25% glycerol cushion at 25,000 r.p.m. for 2 h. For the binding assay, cells (5 × 10 5 ) and virions (MOI of 20) were mixed in a 1.5-ml microcentrifuge tube and incubated on ice for 45 min. After five cycles of centrifugation and washing, cells were lysed in RLT buffer for RNA extraction using an RNeasy Mini Kit (QIAGEN #74104). For the internalization assay, after 5 cycles of centrifugation and washing, cells were resuspended into medium supplemented with 2% FBS and 15 mM NH 4 Cl and then incubated at 37 °C for 1 h. Cells were chilled on ice and treated with 500 ng/ml proteinase K on ice for 1 h. After three additional washes, cells were lysed in RLT buffer for RNA extraction. qRT-PCR was conducted with Gapdh as an internal control using a TaqMan RNA-to-CT 1-Step Kit (Thermo Fisher #4392938). Primers and probes used are as follows: Fwd CHK181/AF: 5′-TCGACGCGCCATCTTTAA-3′; rev CHK181/AF: 5′-ATCGAATGCACCGCACACT-3′; probe CHK181/ AF: 5′ 6-FAM/ACCAGCCTG/ZEN/CACCCACTCCTCAGAC/3′ IABkFQ; fwd Gapdh: 5′-GTGGAGTCATACTGGAACATGTAG-3′; rev Gapdh: 5′-AATGGTGAAGGTCGGTGTG-3′; and probe Gapdh: 5′ 6-FAM/ TGCAAATGG/ZEN/CAGCCCTGGTG/3′ IABkFQ.
For the flow cytometry-based binding assay, experiments were conducted as above but with 5 × 10 4 cells and an MOI of 200. After binding and washing, cells were fixed and stained with a mixture of mAbs (CHK-11, CHK-84, CHK-124 and CHK-166 5 ) (1 μg/ml) at room temperature for 25 min. Cells were washed once and stained with 2 μg/ml of goat anti-mouse IgG (H + L) conjugated with Alexa Fluor 647 (Thermo Fisher #A21235) for 25 min. After two additional washes, cells were subjected to flow cytometry analysis. Surface staining of mouse Mxra8 and human MXRA8. Mouse or human cells were collected with TrypLE and washed twice with cold HBSS supplemented with 15 mM HEPES and 2% FBS. Cells were incubated with anti-Mxra8 (mouse) Armenian hamster serum (1:300), anti-Mxra8 (mouse) hamster mAbs (1 μg/ml) or anti-MXRA8 (human) mAb (1 μg/ml) (MBL International # W040-3) at 4 °C for 25 min. After washing, cells were stained with 2 μg/ml goat anti-Armenian hamster IgG (H + L) conjugated with Alexa Fluor 647 (Abcam #ab173004) or goat antimouse IgG (H + L) conjugated with Alexa Fluor 647 (Thermo Fisher #A21235) for 25 min at 4 °C. After two additional washes, cells were fixed with 2% PFA for 10 min at room temperature. Cells were then washed twice and subjected to flow cytometry analysis. Cell viability assay. A CellTiter-Glo Luminescent Cell Viability Assay (Promega) was performed according to the manufacturer's instructions. In brief, 2 × 10 4 3T3 or MEF cells in 100 μl culture medium were seeded into opaque-walled 96-well plates. 24 h later, 100 μl of CellTiter-Glo reagent was added to each well and allowed to shake for 2 min. After a 10-min incubation at room temperature, luminescence was recorded by using a Synergy H1 Hybrid Plate Reader (Biotek) with an integration time of 0.5 s per well. Western blotting. Cells seeded in 6-well plates were washed once with PBS, chilled on ice in PBS and detached with a cell scraper. After spinning at 300 g for 5 min, cell pellets were lysed in 45 μl RIPA buffer (Cell Signaling #9806S) with a cocktail of protease inhibitors (Sigma-Aldrich # S8830). Samples were prepared in LDS buffer (Life Technologies) under reducing (+dithiothreitol) conditions. After heating (70 °C, 10 min), samples were electrophoresed using 10% Bis-Tris gels (Life Technologies) and proteins were transferred to PVDF membranes using an iBlot2 Dry Blotting System (Life Technologies). Membranes were blocked with 5% non-fat dry powdered milk and probed with hamster mAb 3G2.F5 (0.5 μg/ml) against mouse Mxra8. Western blots were developed using SuperSignal West Pico Chemiluminescent Substrate or SuperSignal West Femto Maximum Sensitivity Substrate (Life Technologies). Alanine scanning mutagenesis for mapping. A CHIKV E2, 6K and E1 envelope protein expression construct (strain S27, Uniprot Reference #Q8JUX5) with a C-terminal V5 tag was subjected to alanine scanning mutagenesis to generate a comprehensive mutation library 36 . Each residue of the envelope proteins was mutated to alanine, with alanine codons mutated to serine. One hundred and forty-one mutations within the E2 A and B domains were screened for binding by Mxra8-Fc. Binding of Mxra8-Fc to each mutant expressed in HEK-293T cells was determined by immunofluorescence detected with a high-throughput flow cytometer (Intellicyt), as previously described 36 . Residues of domains A or B were identified as contributing to the binding site if their mutation eliminated Mxra8-Fc binding, but supported binding of CHIKV mAbs that bind to the appropriate domain (control mAbs were CHKV-84, CHKV-88, IM-CKV063, IM-CKV065 and C9 5, 36, 37 ). Mapping of mutations onto the CHIKV p62-E1 crystal structure. Figures were prepared using the atomic coordinates of CHIKV p62-E1 (RCSB accession number 3N41) using the program PyMOL (The PyMOL Molecular Graphics System, Version 1.7.4 Schrödinger, LLC). mAb generation. Four-week-old male Armenian hamsters were immunized intravenously with 100 μg of purified Mxra8-Fc. After two boosts (~7 months of age), spleens were collected for hybridoma fusion and mAb production. Hybridoma supernatants were initially screened by ELISA using Mxra8-human Fc (mouse Fc was replaced by human Fc). As a second assay, we examined the binding of hybridoma supernatants to Mxra8 on the surface of 3T3 cells by flow cytometry. Finally, a tertiary screen evaluating blockade of CHIKV-181/25 infection by hybridoma supernatants was performed in 3T3 cells. After limiting dilution subcloning, the seven clones with the strongest blocking activities were selected and expanded. Antibodies were purified using protein A sepharose 4B (Invitrogen #101042), dialysed in PBS, concentrated and filtered for in vitro and in vivo experiments. Blocking assays with Mxra8-Fc, MXRA8-2-Fc or anti-Mxra8 mAbs. Twentyfive thousand 3T3 or MRC-5 cells were seeded into 96-well plates 12 h before treatment. CHIKV-181/25 virions were purified through a 25% glycerol cushion at 25,000 r.p.m. for 2 h. Serially diluted Mxra8-Fc or MXRA8-2-Fc protein was incubated with purified virions (MOI of 3) for 1 h at 37 °C in a volume of 100 μl. The mixture was added to 3T3 or MRC-5 cells for 9.5 h or 11.5 h, respectively. Cells were then collected for intracellular E2 expression as measured by flow cytometry. For hamster mAb blocking experiments, 3T3 or MRC-5 cells were preincubated with serially diluted mAbs for 1 h at 37 °C in a volume of 50 μl, and then purified virions (MOI of 3) in 50 μl were added and incubated for 9.5 or 11.5 h, respectively. Cells were collected and intracellular E2 expression was analysed by flow cytometry. For hamster mAb blocking experiments on primary human cells (keratinocytes, dermal fibroblasts, synovial fibroblasts, osteoblasts, chondrocytes and skeletal muscle cells), 2 × 10 4 cells were seeded into 96-well plates 12 h before treatment. Cells were pre-incubated with Armenian hamster isotype control (Bio X Cell # BE0260), 1H1.F5 or 9G2.D6 mAb for 1 h at 37 °C in a volume of 50 μl (50 μg/ml) and, subsequently, purified CHIKV-AF15561 virions (MOI of 15) in 50 μl were added and incubated for 10.5 h. Cells were collected and intracellular E2 expression was analysed by flow cytometry. Phosphatidylinositol-specific phospholipase C treatment. 3T3 cells (10 5 ) expressing GPI-anchored Mxra8 were collected using TrypLE and washed twice with PBS. Cells were then treated with 1 U/ml of phosphatidylinositol-specific phospholipase C (PI-PLC) (Sigma-Aldrich #P8804) in 50 μl PBS at 37 °C for 1 h. After two more cycles of washing, cells were stained for Mxra8 expression and processed by flow cytometry analysis as described above. Mouse experiments. Experiments were carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health after approval by the Institutional Animal Care and Use Committee at the Washington University School of Medicine (Assurance number A3381-01). Mxra8-Fc or an IgG control (JEV-13 mAb) (250 μg per mouse in PBS) was administered via an intraperitoneal route to four week-old wild-type male C57BL/6J mice 6 h before subcutaneous inoculation in the footpad with 10 3 FFU of CHIKV-AF15561. Alternatively, in co-injection experiments, CHIKV or ONNV was mixed directly with Mxra8-Fc or JEV-13 (25 μg per mouse in PBS), and incubated at 37 °C for 30 min before inoculation. At 12 h, 24 h and 72 h post-infection, animals were euthanized, and after perfusion with PBS, indicated tissues were collected. For antibody pre-or post-treatment experiments, 300 μg of purified hamster mAbs 1G11.E6 + 7F1.D8 or 4E7.D10 + 8F7.E1, and isotype control PIP (Bio X cell # BE0260) in PBS were administered via an intraperitoneal route to four weekold wild-type male C57BL/6 mice 12 h prior to, or 8 or 24 h after, subcutaneous inoculation in the footpad with 10 3 FFU of CHIKV-AF15561. Virus was titrated by focus forming assay as described 5 using mouse CHK-11 5 for CHIKV or mouse CHK-48 for ONNV as the detection antibody. Joint swelling was monitored at 72 h post-infection via left foot measurements (width × height) using digital calipers as previously described 38 . Samples sizes were estimated to determine a difference of three-to fivefold, depending on data distribution. Blinding and randomization were not performed. Statistical analysis. Statistical significance was assigned when P values were <0.05 using Prism Version 7 (GraphPad). Cell culture experiments were analysed by multiple t-tests with a Holm-Sidak correction or ANOVA with a multiple comparison correction. Analysis of levels of joint swelling or viral burden in vivo was determined by a Mann-Whitney, ANOVA, Kruskal-Wallis or unpaired t-test depending on data distribution and the number of comparison groups. Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this paper. Data availability. All data supporting the findings of this study are available within the paper and its Supplementary Information. The Supplementary Tables provide data for the CRISPR-Cas9 screen, statistical analysis and alanine scanning mutagenesis mapping of the Mxra8-Fc binding site on CHIKV. All other data are available from the corresponding author upon reasonable request.
Extended Data Fig. 1 | CRISPR-Cas9 -based gene editing screen. a, Mouse 3T3 cells were transduced separately with two half libraries (A + B) comprising 130,209 sgRNAs, selected with puromycin and then inoculated with CHIKV-181/25-mKate2 (MOI of 1). One day later, mKate2-negative cells were sorted and then expanded in the presence of 2 μg ml −1 each of CHK-152 and CHK-166 neutralizing mAbs. Several days later, cells were re-inoculated with CHIKV-181/25-mKate2 without neutralizing mAbs and re-sorted for mKate2-negative cells. This procedure was repeated one additional time. Afterwards, genomic DNA was collected for sgRNA sequencing and compared to the parent library for abundance (see Supplementary Tables 1, 2) . b, Diagram of the mouse Mxra8 and human MXRA8 orthologues. The transcript identification numbers and length of proteins are indicated to the right. Partial deletions in the isoforms 3 and 4 are shown as dashed lines. c, Phylogenetic tree of Mxra8 indicating genetic relationships. The neighbour-joining tree was constructed using MEGA 7 (https://www.megasoftware.net/). Scale bar shows the branch length. Right, identity (red) and similarity (yellow) matrix indicating the conservation of Mxra8 between species. The matrix was generated using MagGat 1.8 (http://iubio.bio.indiana.edu/soft/molbio/ evolve/). Corresponding author(s): Michael Diamond Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.
Please do not complete any field with "not applicable" or n/a. Refer to the help text for what text to use if an item is not relevant to your study. For final submission: please carefully check your responses for accuracy; you will not be able to make changes later.
Experimental design 1. Sample size
Describe how sample size was determined.
We used a power calculation (80% power, 0.05 type I error) to see an 3 to 5-fold effect in vivo (depending on data distribution), which was an n =10.
Data exclusions
Describe any data exclusions.
No data were excluded
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
All cell culture experiments were repeated three independent times. In vivo experiments were performed by multiple laboratory members again with independent repeat experiments. Binding data (SPR and ELISA) were performed by different laboratories and achieved the same result.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups. Not randomized. There was no need to randomized animals for this study. However, the animals were purchased commercially, age-and sex-matched.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Not blinded. Although the study was not blinded, key experiments were repeated independently by multiple members of the laboratory Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated The statistical test(s) used and whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
Test values indicating whether an effect is present
Provide confidence intervals or give results of significance tests (e.g. P values) as exact values whenever appropriate and with effect sizes noted.
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
See the web collection on statistics for biologists for further resources and guidance.
